Literature DB >> 20428190

NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1.

Emilie Sbidian1, Pierre Wolkenstein, Laurence Valeyrie-Allanore, Diana Rodriguez, Smail Hadj-Rabia, Salah Ferkal, Jean-Philippe Lacour, Jean-Claude Leonard, Luc Taillandier, Stéphanie Sportich, Philippe Berbis, Sylvie Bastuji-Garin.   

Abstract

NF-1 is associated with a 15-year decrease in life expectancy. Internal neurofibromas are associated with increased morbidity and mortality through malignant transformation and compression of neighboring organs. Our purpose was to develop and to validate a clinical score for predicting internal neurofibromas in adults. The development sample comprised 208 patients and the validation sample 191 patients. The score was developed using logistic regression. Discrimination and calibration of the model were evaluated. Four variables were independently associated with internal neurofibromas: at least two subcutaneous neurofibromas (odds ratio (OR)=4.7, [2.1-10.5]), age < or =30 years (OR=3.1, [1.4-6.8]), absence of cutaneous neurofibromas (OR=2.6, [0.9-7.5]), and fewer than six café-au-lait spots (OR=2.0 [0.9-4.6]). The score computed by linear combination of the rounded coefficients of these four variables ranged from 0 to 40 (mean, 12.8+/-10.8). The probability of internal neurofibromas was computed as exp (-2.93+0.11Score)/exp (1+(-2.93+0.11Score)). Probabilities agreed well with the observed frequencies indicating good calibration, and discrimination was adequate (AUC-ROC, 0.75) in both data sets. The presence of internal neurofibromas can be accurately predicted using a simple clinical score. Further work will establish the score threshold that identifies patients at high risk for complications.

Entities:  

Mesh:

Year:  2010        PMID: 20428190     DOI: 10.1038/jid.2010.100

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Predicting delayed healing: The diagnostic accuracy of a venous leg ulcer risk assessment tool.

Authors:  Helen E Edwards; Christina N Parker; Charne Miller; Michelle Gibb; Suzanne Kapp; Rajna Ogrin; Jacinta Anderson; Kerrie Coleman; Dianne Smith; Kathleen J Finlayson
Journal:  Int Wound J       Date:  2017-12-26       Impact factor: 3.315

2.  Predicting the likelihood of venous leg ulcer recurrence: The diagnostic accuracy of a newly developed risk assessment tool.

Authors:  Kathleen J Finlayson; Christina N Parker; Charne Miller; Michelle Gibb; Suzanne Kapp; Rajna Ogrin; Jacinta Anderson; Kerrie Coleman; Dianne Smith; Helen E Edwards
Journal:  Int Wound J       Date:  2018-03-13       Impact factor: 3.315

3.  Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.

Authors:  Kavitha Nutakki; Cynthia M Hingtgen; Patrick Monahan; James W Varni; Nancy L Swigonski
Journal:  Health Qual Life Outcomes       Date:  2013-02-21       Impact factor: 3.186

4.  Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France.

Authors:  Tu Anh Duong; Emilie Sbidian; Laurence Valeyrie-Allanore; Cédric Vialette; Salah Ferkal; Smaïl Hadj-Rabia; Christophe Glorion; Stanislas Lyonnet; Michel Zerah; Isabelle Kemlin; Diana Rodriguez; Sylvie Bastuji-Garin; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2011-05-04       Impact factor: 4.123

5.  At-risk phenotype of neurofibromatose-1 patients: a multicentre case-control study.

Authors:  Emilie Sbidian; Sylvie Bastuji-Garin; Laurence Valeyrie-Allanore; Salah Ferkal; Jean P Lefaucheur; Alain Drouet; Pierre Brugière; Cédric Vialette; Patrick Combemale; Sébastien Barbarot; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2011-07-13       Impact factor: 4.123

6.  Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.

Authors:  Scott R Plotkin; Miriam A Bredella; Wenli Cai; Ara Kassarjian; Gordon J Harris; Sonia Esparza; Vanessa L Merker; Lance L Munn; Alona Muzikansky; Manor Askenazi; Rosa Nguyen; Ralph Wenzel; Victor F Mautner
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

7.  Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.

Authors:  Karin S G Cunha; Rafaela E Rozza-de-Menezes; Raquel M Andrade; Amy Theos; Ronir R Luiz; Bruce Korf; Mauro Geller
Journal:  Orphanet J Rare Dis       Date:  2014-12-05       Impact factor: 4.123

8.  Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1.

Authors:  Axel Van Der Gucht; Ouidad Zehou; Soraya Djelbani-Ahmed; Laurence Valeyrie-Allanore; Nicolas Ortonne; Pierre Brugières; Pierre Wolkenstein; Alain Luciani; Alain Rahmouni; Emilie Sbidian; Emmanuel Itti
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

9.  Spinal neurofibromatosis with NF1 mutation in a classic neurofibromatosis type 1 family: A case report and literature review.

Authors:  Zeqian Ning; Zhiqian Yang; Gaofei Chen; Wenjiao Wu; Longshuang He; Yesheng Sun; Dongpeng Cai; Wei Zhang
Journal:  Mol Genet Genomic Med       Date:  2019-11-11       Impact factor: 2.183

10.  Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-selectional study.

Authors:  Emilie Sbidian; Smaïl Hadj-Rabia; Vincent M Riccardi; Laurence L Valeyrie-Allanore; Sébastien Barbarot; Olivier Chosidow; Salah Ferkal; Diana Rodriguez; Pierre Wolkenstein; Sylvie Bastuji-Garin
Journal:  Orphanet J Rare Dis       Date:  2012-09-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.